Subject: To understand the prevalence of genetic mutation, current diagnostic practices & treatment choices in management of ovarian cancer in real world practice
As per Globocan data, incidences of ovarian cancer are 48,014 in India. Till now for the management of first line ovarian cancer combination of chemotherapeutic drugs were being used. With the advent of PARP inhibitors, personalized treatment for patients with genetic mutation positive status are possible.
So far PARP inhibitors were not accessible to all Indian patients due to cost. Considering the fact of it being available in generic space, even diagnostic testing for identification of right patient is increasing. It is crucial to understand current diagnostic testing approaches, treatments choices of doctors for the management of BRCA/HRD+ve patients.
We invite you to participate in this survey and share relevant information about the prevalence of genetic mutations, diagnostic approaches being preferred and treatment modalities being used in your current practice.
We trust you and we are partners in promoting safe effective medical therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})